
Forty Seven
Advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways.
Employees
Enterprise value
$4.9b
Authorizing premium user...
Advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways.